KKH Advisors的动态

We’re excited to announce today the world’s first human procedure of our graphene-based cortical interface in a patient undergoing brain tumor resection. ???? Our BCI tx technology is able to differentiate between healthy and cancerous brain tissue with micrometer-scale precision. The study was sponsored by the The University of Manchester and primarily funded by the European Commission’s Graphene Flagship project. Thank you to Chief Clinical Investigator Dr. David Coope, a neurosurgeon at the Manchester Centre for Clinical Neuroscience and Chief Scientific Investigator Kostas Kostarelos, Ph.D., Professor of Nanomedicine at The University of Manchester, the Catalan Institute of Nanoscience & Nanotechnology, and Co-Founder of INBRAIN. “The world’s first human application of a graphene-based BCI highlights the transformative impact of graphene-based neural technologies in medicine. This clinical milestone opens a new era for BCI technology, paving the way for advancements in both neural decoding and its application as a therapeutic intervention,” said Carolina Aguilar, CEO and Co-Founder of INBRAIN Neuroelectronics. Read the release: ???? https://lnkd.in/eYvtpvrV